Brian Joros, a faculty expert in rheumatology at Northwestern University, and Peter Nash from Griffith University in Brisbane join the discussion. They dive into breakthrough advancements in targeting the IL-17 pathway for rheumatic diseases. Insights from the ACR Annual Meeting reveal impressive MRI remission rates with bemikizumab for ankylosing spondylitis. The duo also explores innovations in psoriatic arthritis treatments, addressing effectiveness, safety, and the nuances of treatment switches during flare-ups, making a case for the evolution of IL-17 therapies.
